Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.

Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review / Casadei Gardini, Andrea; Santini, Daniele; Aprile, Giuseppe; Silvestris, Nicola; Felli, Emanuele; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Marisi, Giorgia; Valgiusti, Martina; Passardi, Alessandro; Puzzoni, Marco; Silletta, Marianna; Brunetti, Oronzo; Cardellino, Giovanni Gerardo; Frassineti, Giovanni Luca; Scartozzi, Mario. - In: ONCOTARGET. - ISSN 1949-2553. - 8:39(2017), pp. 66699-66708. [10.18632/oncotarget.19449]

Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review

Casadei Gardini, Andrea
;
Scartozzi, Mario
2017

Abstract

Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rational to combine them. Though the strategy of combining TACE and sorafenib has been increasingly used in patients with unresectable HCC but the current evidence is controversial and its clinical role has not been determined yet. In first-line therapy, patients receiving sorafenib had increased overall survival and progression free survival. Therefore several antiangiogenic agents have entered clinical studies on HCC, many with negative results. This review discusses the current drug development for patients with HCC and role of TACE plus sorafenib.
8
39
66699
66708
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review / Casadei Gardini, Andrea; Santini, Daniele; Aprile, Giuseppe; Silvestris, Nicola; Felli, Emanuele; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Marisi, Giorgia; Valgiusti, Martina; Passardi, Alessandro; Puzzoni, Marco; Silletta, Marianna; Brunetti, Oronzo; Cardellino, Giovanni Gerardo; Frassineti, Giovanni Luca; Scartozzi, Mario. - In: ONCOTARGET. - ISSN 1949-2553. - 8:39(2017), pp. 66699-66708. [10.18632/oncotarget.19449]
Casadei Gardini, Andrea; Santini, Daniele; Aprile, Giuseppe; Silvestris, Nicola; Felli, Emanuele; Foschi, Francesco Giuseppe; Ercolani, Giorgio; Marisi, Giorgia; Valgiusti, Martina; Passardi, Alessandro; Puzzoni, Marco; Silletta, Marianna; Brunetti, Oronzo; Cardellino, Giovanni Gerardo; Frassineti, Giovanni Luca; Scartozzi, Mario
File in questo prodotto:
File Dimensione Formato  
Antiangiogenic agents after first line and sorafenib plus chemoembolization- a systematic review.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 2.36 MB
Formato Adobe PDF
2.36 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177529
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact